about
Is Modulation of Oxidative Stress an Answer? The State of the Art of Redox Therapeutic Actions in Neurodegenerative DiseasesMelatonin and Other Tryptophan Metabolites Produced by Yeasts: Implications in Cardiovascular and Neurodegenerative DiseasesCellular models to investigate biochemical pathways in Parkinson's diseaseSensorimotor assessment of the unilateral 6-hydroxydopamine mouse model of Parkinson's disease.Molecular imaging of cell death in an experimental model of Parkinson's disease with a novel apoptosis-targeting peptide.Predictive association of copper metabolism proteins with Alzheimer's disease and Parkinson's disease: a preliminary perspective.Selective brain penetrable Nurr1 transactivator for treating Parkinson's disease.Parkinson's disease dementia and potential therapeutic strategies.NADPH oxidase and neurodegenerationMathematical models of α-synuclein transport in axons.The novel tetramethylpyrazine bis-nitrone (TN-2) protects against MPTP/MPP+-induced neurotoxicity via inhibition of mitochondrial-dependent apoptosis.The effect of red grape juice and exercise, and their combination on parkinson(')s disease in ratsNeuroprotective effect of aqueous extract of Selaginella delicatula as evidenced by abrogation of rotenone-induced motor deficits, oxidative dysfunctions, and neurotoxicity in mice.Current understanding of the molecular mechanisms in Parkinson's disease: Targets for potential treatments.Polygalasaponin F against rotenone-induced apoptosis in PC12 cells via mitochondria protection pathway.Animal Toxins as Therapeutic Tools to Treat Neurodegenerative Diseases.Aqueous Extract of Dendropanax morbiferus Leaves Effectively Alleviated Neuroinflammation and Behavioral Impediments in MPTP-Induced Parkinson's Mouse Model.Characteristics of the mitochondrial and cellular uptake of MPP+, as probed by the fluorescent mimic, 4'I-MPP
P2860
Q26765787-29175CB4-64CF-4436-9A18-2104028CE8C3Q26772733-3E2B32C0-2B03-4B76-9722-E39DE1A8D0D3Q26829742-4FBD56B5-788F-4A3D-8137-6D292F831844Q30512976-FDBC64BC-59BA-43B3-96A3-235FAAC613DCQ34184725-0512D00F-F6FE-48C7-A1A1-B989E75A4663Q34398474-BE9407CC-9D1D-47CA-8C23-A1B774F9F0E0Q36946543-7937DBD2-B357-41CA-8248-826435210CE4Q37825631-5226A284-1E0F-4F1F-873F-502E81FE3B57Q38111373-1ED17029-3FB5-4813-A929-E5411496382FQ38981601-323DD041-D447-4E98-8C33-6B739D2258A6Q39063048-CF4428F3-78BB-496C-9CAC-DB4650C143CEQ41497337-B87A49D7-3664-43C9-A3FA-75040835D355Q44593403-298729D0-7686-417B-B332-C297BDC645ECQ45873810-1B8FAE6A-83ED-4891-BAC7-76146AA0F725Q46952414-3AF6BF84-220E-41D2-AAFB-D3F913C307CEQ51764192-80A32E78-04E1-44C9-BDDA-58A9C73EFD4AQ55049102-2A66D614-1479-4229-A13F-94C2C408B560Q58715913-F01780B3-DEF9-401B-9632-ED3190602B4D
P2860
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on March 2009
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Targeting the progression of Parkinson's disease.
@en
Targeting the progression of Parkinson's disease.
@nl
type
label
Targeting the progression of Parkinson's disease.
@en
Targeting the progression of Parkinson's disease.
@nl
prefLabel
Targeting the progression of Parkinson's disease.
@en
Targeting the progression of Parkinson's disease.
@nl
P2093
P2860
P1476
Targeting the progression of Parkinson's disease
@en
P2093
P2860
P356
10.2174/157015909787602814
P577
2009-03-01T00:00:00Z